skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I am looking for some insight to help me understand how the market is currently pricing preferred shares. I had a position in CPD from 2015 to 2020 when I dumped it out of frustration. During that period it seemed that when interest rates were forecast to go up the preferreds would go down because investors would focus on the lower relative yields. If rates were forecast to drop the preferreds would still go down because then investors would focus on the reset aspect. It was an investment that provided the worst of both worlds!

I still hold a couple of preferreds including some fixed perpetuals such as POW.PR.D and RY.PR.P which despite everyone’s expectation of rising interest rates are both hitting new all-time highs now. It’s all just too perplexing for me. Any explanation?
Read Answer Asked by Steven on June 02, 2021
Q: Hello 5i Team
Further to Cam’s question on June 01 regarding BPO.PR.C and related BPO.PR.N
Brookfield Office Properties announced (see Brookfield Property Partners website) at days end on June 01 the new reset dividend rate.
For the readers information, the reset rate is usually stipulated in the prospectus as being set at end of business day 30 days before the reset date. Some companies are very prompt in issuing news releases for preferred reset issues and some are not!
Why do you think Brookfield did not redeem the BPO.PR.C issue? At the new reset rate of 6.117 %, I would have thought BAM/BPY would have been able to raise debt at much lower rate, considering BAM raised debt at sub 3 % in April 2021. Or was this a case of in-opportune timing, with the preferred share issue being available for redemption prior to the closing of the BAM/BPY takeover?
Thanks
Read Answer Asked by Stephen on June 02, 2021
Q: Hi Peter, I've taken some comfort despite my loss on BDX shares because some commentators have pointed out that their products (joint replacements) will soon benefit from the pent-up demand due to Covid-caused delays in such surgeries. However, Stryker, which is in a similar business, has significantly outperformed BDX both before and after Covid. In other words, do you know why BDX is so underperforming SYK, and would you hang onto (or perhaps add to) BDX at this point? Thank you.
Read Answer Asked by James on June 02, 2021
Q: a) Could you please clarify the advantage of owning bep.un vs bepc.
b) Would you recommend adding either to my current holding of aqn/npi/blx?
c) Please list in order of preference
d) Do you think all four would give greater diversity, or would you prefer owning only 2 or 3 of theses companies and if so which ones!
Ed in Montreal
Read Answer Asked by ed on June 02, 2021
Q: hello 5i:
we hold MRK in our portfolio, and have been notified of the allotment, as of 2 June, of shares of Organon. Can you discuss how you will see MRK shares being affected and whether or not you think the new Organon shares will have opportunities in the future that MRK did not have. Said another way, do you see this as beneficial to existing shareholder and does the new company hold some promise. CSU and TOI come to mind
thanks
Paul L
Read Answer Asked by Paul on June 01, 2021
Q: Greetings,

I have 4% cash currently and would consider short term opportunities. With a new competing bid IPL is trading below the offer price. Do you see an opportunity here to purchase IPL and hold for the sale and possible counter offer? Or is the difference more related to the half cash half PPL stock offer which will be more volitile? Hence risk. I appreciate your insite.

Cheers!
Read Answer Asked by Duane on June 01, 2021
Q: Regarding todays nr, is it safe to assume the observations from the clinical trial are in a positive light? I have a small position and am considering adding - since the casino is closed. London, Ontario-TheNewswire -June 1, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF)(FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a presentation at the upcoming American Transplant Congress (ATC) Virtual Connect to be held June 4 - 9, 2021.
Read Answer Asked by Charles on June 01, 2021